Researchers treated the first patient with a rare mitochondrial myopathy using the patient’s own stem cells, demonstrating safety and improved muscle strength, according to a recently published press release.
A rare mitochondrial myopathy refers to a group of genetic disorders including Thymidine Kinase 2 deficiency (TK2d) in which faulty mitochondria in muscle cells can’t produce enough energy, causing progressive muscle weakness, fatigue, exercise intolerance and potentially affecting the heart, brain, and other organs.
The press release described an innovative stem cell therapy for a rare genetic muscle disorder caused by mitochondrial dysfunction. Maastricht researchers extracted healthy stem cells from the patient’s own muscle tissue, expanded them in the lab and infused them back into the bloodstream. Early results indicate that the treatment is safe and is associated with increased muscle strength, offering hope for a potential new treatment in the future.
Historically, treatments for disorders like mitochondrial myopathies have focused on symptom management because underlying cellular defects couldn’t be corrected; this study marks a shift toward regenerative approaches.
“We extract these healthy stem cells from a muscle biopsy and multiply them in the laboratory…the cells get to work and produce muscle fibres, which can increase muscle strength and reduce fatigue,” the authors wrote.
The authors aimed to evaluate whether autologous stem cells can be safely used to treat a rare mitochondrial muscle disease and to see if these cells can increase muscle strength and reduce fatigue in affected patients.
In this early clinical study, researchers harvested healthy stem cells from a patient’s muscle biopsy, expanded the cells in culture, and then infused them back into the patient’s bloodstream. They monitored safety and muscle strength, finding no serious side effects and an increase in muscle strength after treatment. As a next step, the larger follow-up study will test whether these benefits extend to a broader patient population. A stronger design could include a randomized control group and standardized outcome measures to assess treatment effectiveness more rigorously across a larger cohort.
“For all these people, improving muscle strength means greater independence and a better quality of life,” the authors wrote.
Sign up here to get the latest news, perspectives, and information about TK2d sent directly to your inbox. Registration is free and only takes a minute.